FOLETTA MARK G 4

4 · DEXCOM INC · Filed Jun 17, 2026

AI-generated summary of this filing

Updated Jun 17, 2026

DexCom (DXCM) Director Mark Foletta Sells 4,000 Shares

What Happened

Mark G. Foletta, a director of DexCom, reported the sale of a total of 4,000 shares of DexCom common stock on June 15, 2026. The sales consisted of 3,801 shares at a weighted average price of $74.10 ($281,651) and 199 shares at a weighted average price of $74.82 ($14,889), for combined proceeds of about $296,540. These were dispositions (sales), not purchases or option exercises.

Key Details

Transaction dates: June 15, 2026; Form 4 filed June 17, 2026 (appears timely for a Form 4 covering a June 15 trade).
Prices: weighted averages shown of $74.10 (for 3,801 shares) and $74.82 (for 199 shares). Filing notes the 3,801-share block traded in multiple trades at $73.70–$74.685 (F2) and the 199-share block at $74.78–$75.55 (F4); the filing offers to provide per-trade details on request.
Holdings after transaction: not specified in the provided excerpt of the filing.
Notable footnotes:
- F1/F3: The shares were held by The Foletta Family Trust DTD 1/30/2015; Mr. Foletta is a trustee and the sales were made pursuant to a 10b5-1 trading plan adopted March 13, 2026.
- F2/F4: Multiple-trade execution and weighted-average pricing; reporting person will provide trade-level details on request.
- F5 (separate): The filing also references unvested RSUs granted May 28, 2026 that vest the earlier of one year after grant or the 2027 annual meeting (not part of these sales).

Context

These were open-market sales of trust-held shares executed under a pre-established 10b5-1 plan, which is a common mechanism directors use to sell shares on a preset schedule. Sales under a 10b5-1 plan typically indicate pre-planned disposals rather than ad hoc insider selling; the filing itself does not state motivations. This transaction does not involve option exercises, gifts, or company-awarded shares being sold as part of a cashless exercise.

Form 4

Period: 2026-06-15

Director

Transactions

Sale
Common Stock
[F1][F2][F3]
2026-06-15$74.10/sh−3,801$281,651→ 53,051 total(indirect: By Trust)
Sale
Common Stock
[F1][F4][F3]
2026-06-15$74.82/sh−199$14,889→ 52,852 total(indirect: By Trust)

Holdings

Footnotes (5)

[F1]On March 13, 2026, The Foletta Family Trust DTD 1/30/2015 (the "Trust") adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan.
[F2]This transaction was executed in multiple trades at prices ranging from $73.70 to $74.685. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
[F3]Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the Reporting Person is a trustee.
[F4]This transaction was executed in multiple trades at prices ranging from $74.78 to $75.55. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
[F5]Represents unvested restricted stock units which were granted on May 28, 2026 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders.

Signature

/s/ Jereme M. Sylvain, as Attorney-in-Fact for Mark G. Foletta|2026-06-17

1 file